The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD

VILAR-GOMEZ, EDUARDO; PIROLA, CARLOS J.; SOOKOIAN, SILVIA; WILSON, LAURA A.; LIANG, TIEBING; CHALASANI, NAGA

Clinical and Translational Gastroenterology

NATURE PUBLISHING GROUP

Lugar: New York; Año: 2021 vol. 12 p. 400 - 412

INTRODUCTION: Our study aimed to explore how PNPLA3 rs738409 or phenotypic risk factors may moderate the relationship between HSD17B13 rs72613567 and risk of steatohepatitis and fibrosis.METHODS: This analysis consisted of 1,153 non-Hispanic whites with biopsy-proven nonalcoholic fatty liver disease enrolled in the nonalcoholic steatohepatitis Clinical Research Network studies.Nonalcoholic fatty liver disease severity was determined by liver histology scored centrally according to the nonalcoholic steatohepatitis Clinical Research Network criteria. Moderation and logistic regression analyses were performed to identify the influence of moderators (PNPLA3 rs738409, age, sex, body mass index, and diabetes) on the relationship between HSD17B13 rs72613567 and risk of steatohepatitis and fibrosis.RESULTS: HSD17B13 rs72613567 genotype frequency was as follows: (2/2), 64%; (2/A), 30%; (A/A), 6%. Moderation analysis showed that the protective effect of HSD17B13 rs72613567 A-allele on risk of steatohepatitis remained only significant among patients with PNPLA3 rs738409 genotype CC (b coeff: 20.19, P50.019), women (b coeff:20.18, P,0.001), patients of age ? 45 years (b coeff:20.18, P:0.001), patientswith bodymass index? 35kg/m2 (bcoeff:20.17,P,0.001), and patients with diabetes (b coeff:20.18, P5 0.020). Among women, the protective effect of HSD17B131 rs72613567 A-allele on risk of steatohepatitis was stronger in those aged ? 51 years. Logistic regression-based sensitivity analysis including various important subgroups confirmed our observations.DISCUSSION: The protection conferred by HSD17B13 rs72613567 A-allele on risk of steatohepatitis and fibrosis may be limited to selected subgroups of individuals who are aged ? 45 years, women and have class ? 2 obesity or diabetes, and those with PNPLA3 rs738409 CC genotype.